Gender-specific differences in recurrence and progression following BCG instillation for NMIBC.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2024-11-07 DOI:10.1159/000542473

Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Friedemann Zengerling, Angelika Borkowetz, Sebastian Graf, Annabel Graser, Annemarie Uhlig

{"title":"Gender-specific differences in recurrence and progression following BCG instillation for NMIBC.","authors":"Laila Schneidewind, Bernhard Kiss, Jennifer Kranz, Friedemann Zengerling, Angelika Borkowetz, Sebastian Graf, Annabel Graser, Annemarie Uhlig","doi":"10.1159/000542473","DOIUrl":null,"url":null,"abstract":"Introduction: To assess gender-specific differences in recurrence-free (RFS), progression-free (PFS), cancer-specific survival (CSS) and overall survival (OS) among patients with intermediate or high-risk non-muscle invasive bladder cancer (NMIBC) receiving BCG is the primary aim of this systematic review and meta-analysis.Methods: In July 2023, we performed a literature search using MEDLINE, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD.Results: The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females=0.9618, 95% CI: 0.8408-1.1003, p=0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR =0.9540, 95% CI: 0.7709- 1.1805, p=0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR =0.9228, 95% CI: 0.6196-1.3743, p=0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092-2.5684, p=0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias.Conclusion: The findings indicate no association between gender and oncologic outcomes following BCG.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-17"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: To assess gender-specific differences in recurrence-free (RFS), progression-free (PFS), cancer-specific survival (CSS) and overall survival (OS) among patients with intermediate or high-risk non-muscle invasive bladder cancer (NMIBC) receiving BCG is the primary aim of this systematic review and meta-analysis.

Methods: In July 2023, we performed a literature search using MEDLINE, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD.

Results: The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females=0.9618, 95% CI: 0.8408-1.1003, p=0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR =0.9540, 95% CI: 0.7709- 1.1805, p=0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR =0.9228, 95% CI: 0.6196-1.3743, p=0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092-2.5684, p=0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias.

Conclusion: The findings indicate no association between gender and oncologic outcomes following BCG.

查看原文本刊更多论文

卡介苗注射治疗 NMIBC 后复发和病情发展的性别差异。

简介本系统综述和荟萃分析的主要目的是评估接受卡介苗治疗的中高危非肌浸润性膀胱癌（NMIBC）患者在无复发（RFS）、无进展（PFS）、癌症特异性生存（CSS）和总生存（OS）方面的性别差异：2023 年 7 月，我们使用 MEDLINE、Embase 和 Cochrane 图书馆进行了文献检索。本研究在 PROSPERO（CRD 2023443269）上进行了前瞻性注册。详细的综述方案可通过 CRD 查阅：系统性文献检索共发现 6723 项研究，其中 38 项符合纳入标准。基于24项研究数据的RFS随机效应荟萃分析显示，性别差异无统计学意义（男性与女性比较的HR=0.9618，95% CI：0.8408-1.1003，P=0.5707）。同样，对于 PFS，结合 14 项研究的数据，也没有统计学意义上的显著差异（HR =0.9540，95% CI：0.7709- 1.1805，P=0.6648）；对于 CSS，分析 3 项研究的数据，也没有统计学意义上的显著差异（HR =0.9228，95% CI：0.6196-1.3743，P=0.6925），而对于OS，根据两项研究的数据，未观察到有统计学意义的差异（HR=1.1436，95% CI：0.5092-2.5684，P=0.7452）。偏倚风险评估表明，总体偏倚风险为中度至高度：研究结果表明，卡介苗治疗后，性别与肿瘤结果之间没有关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.